March 27 (Reuters) - Eli Lilly ( LLY ) said on Friday

that its eczema drug showed durable results in a late-stage

post-marketing study, such as  relief from persistent  itch for

up to four years in patients with the skin condition.

Here are more details:

* A once-monthly injection of the drug, Ebglyss -

approved in the United States in 2024 - showed durable response

in patients with moderate-to-severe atopic dermatitis, which

causes intense itching.

* The injectable treatment is approved for adults and

children 12 years and older with moderate-to-severe eczema who

cannot use topical therapies.

* In the study, majority of patients achieved near-complete

skin clearance and itch relief with up to four years of

continuous treatment, Lilly said.

* Ebglyss' safety in the first year of the study was

consistent with its known profile, regardless of dosing

frequency, and no new safety issues were observed, the company

said.

* The study will continue for an additional year of

treatment.

* Lilly last year reported results from another trial

showing Ebglyss provided a durable response when dosed every

four or eight weeks. The drugmaker said it has submitted the

data to the U.S. Food and Drug Administration for a potential

label update.